Colorectal Cancer Clinical Trial
Official title:
Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System
To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III clinical trial.
Human epidermal growth factor receptor 2, (HER2) is overexpressed /amplified in multiple
carcinomas, for example, gastric cancer(GC), gastroesophageal junction
adenocarcinoma(GEJA),and breast cancer.And HER2 is closely related to tumor proliferation
&metastases.About 90% Chinese esophagus cancer are squamous cell origin. The reported HER2
overexpression ranged from 5-30%, Beijing cancer hospital reported an 11% positive rate. The
variety of HER2 positive rate may because of the absence of standard HER2 testing criteria.
The current treatment for metastatic Esophageal squamous Cell Carcinoma (ESCC) is not
satisfactory. Fluorouracil and platinum are considered as first line standard of care (SOC)
with a 20-30% RR and 7-9 months overall survival (OS). In second line setting, there is no
SOC in china. And the efficacy is not satisfactory. Esophageal adenocarcinoma has a higher
HER2 positive rate of 14%, but no data reported of using trastuzumab in these patients in
China. Biliary tract cancer (BTC), including intrahepatic/extrahepatic cholangiocarcinoma and
Gallbladder cancer (GBC) is very aggressive, total 5y survival is less than 5% for
unresectable patients. GBC is account for approximately 2/3 of BTC, and it's estimated the
incidence in china is 52800 and the mortality is 40700 in 2015. Most patients are diagnosed
in advanced stage and lose the opportunity of surgery. However, there is no SOC for
unresectable BTC, gemcitabine plus platinum provided a 30% RR and 10 month OS. In second line
treatment, no differences were seen between various experimental agents. The reported HER2
positive rate range from 5.1% to 57% in biliary duct cancer and 4.7% to 64% in GBC.
Researchers reported her2 amplification is related to tumor stage and lymph nodes metastasis
in 221 BTC patients. Another study reported a 16.6% positive rate and worse prognosis with a
sample size of 230 GBC patients. Meanwhile, HER2 pathway mutation rate reached 37%. All imply
that BTC may be the potential anti HER therapy population. Besides, other digestive system
tumor has low HER2 positive rate (Small intestinal cancer 0.9-3%; hepatocellular carcinoma
2.4%; Pancreatic cancer 3%; etc.). However, the patient pool is large and has no SOC in
second Line. Whether these HER2 + patients can gain benefit form anti- her treatment is worth
investigating. In 2016 American Society of Clinical Oncology (ASCO), a study reported that
using trastuzumab and pertuzumab combination, 35% metastatic colorectal cancer (CRC) and 50%
BTC patients who heavily pretreated had objective response. However, china doesn't have
studies for these patients. .
The concurrent basket trial will explore the efficacy and safety of trastuzumab with
chemotherapy in Chinese patients of pretreated, HER2 positive, relapse or metastatic
carcinoma of digestive system.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |